Infusion Pumps Market Outlook, 2030

Infusion pumps are medical devices used to deliver fluids such as medications, nutrients, and insulin into a patient’s body in controlled amounts, and their demand is surging across both hospital and home care settings. For instance, growing patient population in diabetes, cancer, and neurological disorders has resulted in growing demand for long term care preferably at home care settings. With over 500 million people currently living with diabetes and cancer cases rising annually, infusion therapy has become a cornerstone of chronic care.

Additionally, the world's aging population expected to reach over 1.5 billion aged 65 and above by 2050 significantly fuels the need for advanced infusion systems to manage age-related illnesses, postoperative recovery, and pain control. According to the World Health Organization (WHO), in 2018, cancer was estimated to be the second most prominent cause of death globally and is responsible for about 9.6 million deaths. Cancer patients require chemotherapy which is to be delivered to the patients in a continuous manner which can be achieved by using the pump. Key manufacturers, including BD, Baxter, ICU Medical, and Medtronic, have faced product recalls due to safety concerns. Most recently, in January 2023, Baxter issued a recall for the SIGMA Spectrum Infusion Pumps with Master Drug Library (Version 8) and Spectrum IQ Infusion Systems with Dose IQ Safety Software (Version 9). This action was prompted by a rise in reports of false upstream occlusion alarms following software upgrades to versions v8.01.01 and v9.02.01. However, due to the unavailability of workers and supply chain disruptions, there was a decline in the production due to the COVID-19 pandemic. For instance, Baxter international has experienced significant and unpredictable reductions and increases in the demand of certain healthcare products during the COVID-19 pandemic. However, new product launches have uplifted the revenue growth in the year 2020. For instance, In January 2020, Medtronic, Ireland has launched Efficio networked with the SynchroMed II intrathecal drug delivery system.

According to the research report “Global Infusion Pumps Market Outlook, 2030”, the Global Infusion Pumps market is projected to reach market size of USD 27.92 Billion by 2030 increasing from USD 18.21 Billion in 2024, growing with 7.54% CAGR by 2025-30. Patients, particularly those with chronic diseases or undergoing long-term therapies like chemotherapy or parenteral nutrition, are now more inclined toward receiving treatment in the comfort of their homes. This shift has spurred demand for compact, battery-operated, and user-friendly infusion devices, including ambulatory and elastomeric pumps.

Moreover, growing geriatric population in need of long-term care therapies is driving the new product developments targeting home-based infusion therapies. In August 2020, Ivenix, Inc. has developed a smart infusion pump named as Epic which helps to eliminate infusion-based injuries of patients. For instance, as per the data provided by Elite Biomedical Solutions, LLC in December 2021, ambulatory pumps are lightweight and provide mobility for patients needing continuous IV infusions. Moreover, increasing product recalls due to product errors are restricting the market growth. Also, the U.S. FDA has made a statement regarding the infusion pump recall. According to the FDA, more than 50,000 units of the Model 4000 syringe pumps received product recall for correction. These infusion pumps were distributed from November 2010 to July 2023. In August 2019, for example, Fresenius Kabi recalled Vigilant Agilia drug library and Volumat MC Agilia infusion pump due errors to an infusion alarm, low priority keep vein open (KVO), and multiple errors associated with software. Clinical research activities involving infusion-related drug delivery are expanding rapidly, showcasing promising developments in therapeutic applications. For instance, in November 2022, TriSalus Life Sciences initiated comprehensive studies (PERIO 01 and PERIO 02) focusing on primary and metastatic liver tumors, utilizing their FDA-cleared TriNav Infusion System. This research demonstrates the growing sophistication of infusion technologies in targeted therapy delivery, particularly in oncology applications, where precision and control are crucial.

Market Drivers

• Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is a major driver for the global infusion pumps market. Patients suffering from these ailments often require continuous, accurate, and controlled delivery of medications, including chemotherapy drugs, insulin, or pain relievers. Infusion pumps ensure precise dosage and timing, reducing the risk of human error and improving treatment outcomes. As global life expectancy rises and the elderly population grows who are more susceptible to chronic illnesses the demand for long-term and home-based care is also surging. This directly increases the need for infusion pump solutions across healthcare settings.
• Technological Advancements and Smart Infusion Systems: Rapid innovation in infusion pump technologies is propelling market growth. The integration of wireless connectivity, drug libraries, real-time monitoring, and automation in infusion systems has greatly enhanced their accuracy and safety. Smart infusion pumps help reduce medication errors by providing alerts, dosage checks, and automatic documentation. These systems are increasingly integrated with hospital electronic health records (EHRs), enabling seamless data flow and improved clinical decision-making. The push for more intelligent and user-friendly devices has expanded applications across various medical settings from hospitals and ICUs to ambulatory care and home healthcare.

Market Challenges

• Stringent Regulatory Requirements and Product Recalls: The infusion pumps industry is heavily regulated, with devices requiring rigorous clinical testing, quality control, and regulatory approvals before market entry. Regulatory bodies such as the U.S. FDA or EMA have high standards for safety and efficacy, often resulting in lengthy approval timelines and significant compliance costs. Moreover, infusion pumps have been frequently subjected to product recalls due to malfunctions, software errors, or design flaws. Such recalls not only affect manufacturer reputation but also create trust issues among healthcare providers, impeding broader adoption.
• High Cost of Advanced Infusion Systems: Although technologically advanced infusion pumps offer superior functionality, their high upfront cost and ongoing maintenance expenses present a barrier, particularly in developing economies. Healthcare facilities in low-resource settings often struggle with budget constraints and may opt for cheaper, less advanced alternatives. The total cost of ownership, including staff training, regular servicing, and software upgrades, can be significant. This price sensitivity limits the market penetration of sophisticated infusion technologies in rural or underfunded healthcare systems, despite the clinical benefits they offer.

Market Trends

• Shift Toward Home Healthcare and Ambulatory Infusion: There is a growing trend of administering infusion therapy in outpatient or home-based settings, driven by patient preference for convenience and cost-effective care. Portable and wearable infusion pumps are becoming more common, allowing patients to maintain daily routines while receiving necessary treatments such as pain management, antibiotics, or nutritional support. This trend is also encouraged by healthcare systems looking to reduce hospital overcrowding and lower inpatient care costs. Consequently, manufacturers are focusing on developing lightweight, compact, and easy-to-use infusion devices suitable for at-home use.
• Integration of AI and IoT for Enhanced Monitoring: The infusion pumps market is increasingly adopting AI (Artificial Intelligence) and IoT (Internet of Things) technologies to improve patient safety and treatment efficiency. Smart pumps with AI capabilities can predict dosing errors, detect occlusions early, and adapt flow rates based on real-time patient feedback. IoT-enabled devices can transmit usage data to cloud platforms, allowing healthcare providers to monitor infusion parameters remotely and intervene when anomalies are detected. These advancements contribute to personalized medicine, remote diagnostics, and better patient engagement, marking a significant transformation in infusion therapy delivery.

The rising global prevalence of diabetes and the increasing preference for continuous, precise insulin delivery systems are driving the dominance of insulin pump types in the global infusion pumps industry.

Insulin pumps are leading the global infusion pumps industry primarily due to the accelerating burden of diabetes worldwide, coupled with a growing patient and healthcare provider preference for advanced and more efficient methods of insulin delivery. According to the International Diabetes Federation (IDF), over 530 million people were living with diabetes in 2021, and this number is projected to exceed 640 million by 2030. With this dramatic rise in diabetes cases, there is an escalating demand for precise, automated, and patient-friendly insulin administration solutions needs that insulin pumps meet far more effectively than traditional insulin injections.

Insulin pumps offer continuous subcutaneous insulin infusion (CSII), allowing for more stable glycemic control, reduced risk of hypoglycemia, and enhanced patient convenience. These benefits are especially crucial for Type 1 diabetes patients who require round-the-clock insulin management, making pumps a preferred choice over multiple daily injections (MDI). Moreover, governments and private payers in developed regions like North America and Europe are offering reimbursement support for insulin pump use, making them more accessible to a larger patient base. In emerging economies, rising income levels, improving healthcare infrastructure, and growing urbanization are also fostering market expansion. Leading players in the medical devices sector are investing heavily in insulin pump innovations, thereby expanding product availability and functionality. With these developments, insulin pumps are not only gaining prominence among end-users but are also being increasingly recommended by endocrinologists and diabetes specialists.

The dominance of diabetes management applications in the global infusion pumps industry is driven by the rapidly growing diabetic population and the increasing demand for precise, continuous.

Diabetes management has emerged as the leading application type in the global infusion pumps industry due to the escalating prevalence of diabetes and the urgent need for consistent, safe, and efficient insulin administration. Globally, diabetes is becoming one of the most common chronic conditions, with the International Diabetes Federation estimating that the number of adults living with diabetes will rise to over 640 million by 2030. Unlike traditional methods of insulin administration, infusion pumps provide greater flexibility, improved glucose regulation, and reduced risk of both hypoglycemia and hyperglycemia. These devices enable patients, particularly those with Type 1 diabetes, to lead more active and less restrictive lifestyles.

With technological advancements such as the integration of continuous glucose monitors (CGMs), mobile connectivity, and closed-loop systems (also known as artificial pancreas systems), diabetes management through infusion pumps is becoming smarter, more accurate, and increasingly automated. This integration not only enhances treatment outcomes but also reduces the burden on healthcare systems by minimizing hospital visits and complications. Additionally, increasing patient education and awareness, along with support from healthcare providers and insurance reimbursement in many developed countries, are making infusion-based diabetes management more accessible and appealing.

Traditional infusion pump technology leads the global infusion pumps industry due to its widespread clinical acceptance, proven reliability, and cost-effectiveness across diverse healthcare settings.

Traditional infusion pump technology continues to dominate the global infusion pumps industry because of its long-established track record of safety, effectiveness, and adaptability in administering a wide range of medications, nutrients, and fluids. These pumps, including volumetric and syringe pumps, are extensively used in hospitals, clinics, and outpatient care facilities to deliver precise, controlled amounts of drugs over extended periods. Their simple interface, robust mechanical design, and compatibility with multiple types of therapies ranging from chemotherapy to pain management and critical care make them indispensable tools in both acute and chronic care.

While newer technologies like smart and wearable pumps are emerging, traditional pumps remain the gold standard for many healthcare providers due to their consistent performance, ease of use, and minimal training requirements. Moreover, the reliability of traditional infusion pumps in critical care environments such as intensive care units (ICUs), emergency rooms, and surgical settings further underpins their dominance. In situations where accurate drug delivery and uninterrupted operation are vital, healthcare professionals continue to rely on traditional systems they trust. Manufacturers of traditional pumps are also continuously upgrading their devices with incremental improvements such as enhanced alarms, better battery life, and improved user interfaces without transitioning to fully digital systems. This strategy ensures that traditional pumps stay relevant while maintaining their core functional strengths.

Stationary infusion pumps are leading in the global infusion pumps industry due to their critical role in hospital-based care, offering high precision, continuous monitoring, and compatibility with a wide range of therapies in controlled clinical environments.

Stationary infusion pumps maintain a leading position in the global infusion pumps industry primarily because they are essential components of hospital and clinical care, where precision, reliability, and continuous drug delivery are crucial. These pumps are predominantly used in intensive care units (ICUs), operating rooms, emergency departments, and inpatient wards to administer critical medications such as antibiotics, chemotherapy agents, anesthetics, and total parenteral nutrition (TPN). Their ability to handle complex, high-volume, or high-risk infusions with a high degree of accuracy makes them indispensable in acute care settings.

Unlike portable or ambulatory pumps, stationary pumps are designed for continuous, uninterrupted operation, often integrated with centralized monitoring systems that enable healthcare professionals to closely manage multiple patients simultaneously. The dominance of stationary infusion pumps is also supported by healthcare infrastructure investments in both emerging and developed markets. As hospital capacities expand and more ICUs and surgical units are established to meet rising patient demand, the need for dependable stationary infusion systems grows proportionally. Furthermore, regulatory preferences and procurement policies often favor stationary models for use in public healthcare systems due to their standardized features and proven performance history. Manufacturers are continuously improving stationary infusion pumps with enhanced safety features, data integration capabilities, and compatibility with hospital information systems (HIS) and electronic medical records (EMRs), which strengthens their role in modern healthcare delivery.

Hospitals are the leading end-user type in the global infusion pumps industry due to their high demand for accurate, continuous, and multi-therapy drug delivery systems essential for managing acute, chronic, and critical care patients.

Hospitals dominate the global infusion pumps industry because they are the primary settings for administering complex, continuous, and precisely dosed treatments to patients requiring acute and critical care. These healthcare institutions rely heavily on infusion pumps for a wide array of clinical applications, including the delivery of antibiotics, chemotherapy, analgesics, insulin, blood products, and intravenous fluids. Infusion pumps are indispensable in intensive care units (ICUs), operating rooms, emergency departments, and general wards, where patient conditions often require constant monitoring and tightly controlled medication delivery.

Given the complexity and severity of conditions treated in hospitals, the need for technologically advanced, reliable, and high-performance infusion systems is paramount fueling consistent demand and making hospitals the most significant consumer segment in this market. Hospitals benefit from centralized infrastructure and highly trained medical personnel who can effectively manage and maintain infusion technologies. This professional environment enables the optimal use of programmable infusion pumps and integration with electronic health record (EHR) systems, ensuring medication accuracy and patient safety. Additionally, hospitals typically handle patients with multiple comorbidities or those undergoing surgery, trauma care, or intensive therapies, all of which require customized infusion regimens that stationary and multi-channel pumps can deliver with precision. The ability of hospitals to purchase in bulk, negotiate procurement contracts, and comply with strict regulatory and safety standards also supports the widespread deployment of infusion pumps across departments.

North America is leading in the global infusion pumps industry due to its advanced healthcare infrastructure, high healthcare expenditure, and strong presence of key market players driving innovation and adoption.

North America's dominance in the global infusion pumps industry is primarily attributed to its well-established and technologically advanced healthcare infrastructure, which enables faster adoption of innovative medical devices. The region, particularly the United States, has a high concentration of hospitals, ambulatory surgical centers, and specialty clinics that rely heavily on infusion pumps for delivering fluids, medications, and nutrients with precision and safety. Moreover, the region benefits from one of the highest healthcare expenditures per capita globally, with significant investments made in modernizing hospital equipment and implementing automated solutions to improve patient care.

These financial resources support the integration of advanced infusion technologies, including smart pumps with wireless connectivity and drug library features, enhancing medication safety and clinical efficiency. North America also houses many of the leading manufacturers and innovators in the infusion pump space, such as Becton, Dickinson and Company (BD), Baxter International Inc., ICU Medical, and Medtronic. These companies continuously invest in research and development to introduce new, safer, and more efficient infusion systems, further propelling the region's market leadership. Additionally, the region’s regulatory landscape, although stringent, is transparent and well-structured, which accelerates the approval and commercialization of novel infusion devices. North America has witnessed growing adoption of home infusion therapy, supported by favorable reimbursement policies and increasing preference for outpatient care. Furthermore, the aging population in countries like the U.S. and Canada adds to the need for infusion therapies, given the higher incidence of chronic conditions among the elderly.

• In April 2025, Becton, Dickinson and Company received FDA clearance for BD Alaris Infusion System with Guardrails Suite MX (including modules like PC Unit, Pump, Syringe, PCA, EtCO2, Auto-ID, and System Manager) as safe and effective for market use. This clearance confirms the system is substantially equivalent to previously approved devices and can now be legally sold in the US.
• In January 2025, Becton, Dickinson and Company invested in its US manufacturing network to add capacity for critical medical devices, including syringes, needles, and IV catheters, to meet the ongoing needs of the nation's healthcare system.
• In December 2023, Fresenius Kabi AG announced that it had signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona, and Florida.
• In September 2022, B. Braun SE acquired the innovative Clik-FIX catheter securement device portfolio from Starboard Medical, Inc. This acquisition builds on B. Braun’s history of product and program innovation to improve the patient experience and outcomes with peripheral intravenous (IV) therapy.